1. Koumpouros Y. in Chronic Pain. Unveiling Technological Advancements and Interdisciplinary Solutions for Pain Care. 2025: 37. [ DOI:10.4018/979-8-3693-9501-1] 2. Smith ESJ, Lewin GR. Nociceptors: a phylogenetic view. Journal of Comparative Physiology A. 2009; 195(12): 1089-106. [ DOI:10.1007/s00359-009-0482-z] 3. Gavva NR. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends in Pharmacological Sciences. 2008; 29(11): 550-7. [ DOI:10.1016/j.tips.2008.08.003] 4. Woolf CJ, Ma Q. Nociceptors-noxious stimulus detectors. Neuron. 2007; 55(3): 353-64. [ DOI:10.1016/j.neuron.2007.07.016] 5. Nazari-Srenjeh f, ghasemzadeh z. Brain Regions and Neurotransmitter Systems Involved in Stress-Induced Analgesia. The Neuroscience Journal of Shefaye Khatam. 2024; 13(1): 104-15. [ DOI:10.61186/shefa.13.1.104] 6. Abbott GW, Manville RW. NaVigating nociceptive neuron signaling pathways to arrive at pain relief. The Journal of pharmacology and experimental therapeutics. 2025; 392(2). [ DOI:10.1016/j.jpet.2024.100037] 7. Andrade ACM, Molina Esquivel N, Goldschmied Rossel F, Benso B. TRPV1-target drugs for the treatment of orofacial pain. Frontiers in Pharmacology. 2025; 16: 1568109. [ DOI:10.3389/fphar.2025.1568109] 8. Mansoor SE, Lü W, Oosterheert W, Shekhar M, Tajkhorshid E, Gouaux E. X-ray structures define human P2X3 receptor gating cycle and antagonist action. Nature. 2016; 538(7623): 66-71. [ DOI:10.1038/nature19367] 9. Alpes A, Malek S, Baron R. TRPV1 is the burner. Pain. 2025; 166(4): 717-8. [ DOI:10.1097/j.pain.0000000000003542] 10. Khanizadeh A-M, Karimzadeh F. Experimental Models of Rheumatoid Arthritis: Acute and Chronic Pain. The Neuroscience Journal of Shefaye Khatam. 2017; 5(1): 98-109. [ DOI:10.18869/acadpub.shefa.5.1.98] 11. Devesa I, Fernández-Ballester G, Fernandez-Carvajal A, Ferrer-Montiel A. A review of the patent literature surrounding TRPV1 modulators. Expert Opinion on Therapeutic Patents. 2025; 35(5): 477-91. [ DOI:10.1080/13543776.2025.2467698] 12. González J, Palma JM, Benso B, Valdés-Muñoz E, Urra G, Ríos-Rozas SE, et al. Integrative Computational Approaches for TRPV1 Ion Channel Inhibitor Discovery: An Integrated Machine Learning, Drug Repurposing and Molecular Simulation Approach. Journal of Chemical Information and Modeling. 2025; 65(17): 8957-68. [ DOI:10.1021/acs.jcim.5c00991] 13. Wallace M, Pappagallo M. Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia. Expert Rev Neurother. 2011; 11(1): 15-27. [ DOI:10.1586/ern.10.182] 14. Neuberger A, Oda M, Nikolaev YA, Nadezhdin KD, Gracheva EO, Bagriantsev SN, et al. Human TRPV1 structure and inhibition by the analgesic SB-366791. Nature communications. 2023; 14(1): 2451. [ DOI:10.1038/s41467-023-38162-9] 15. Mamatova KN, Kang TM. Activation of rat transient receptor potential cation channel subfamily V member 1 channels by 2-aminoethoxydiphenyl borate. Integr Med Res. 2013; 2(3): 112-23. [ DOI:10.1016/j.imr.2013.06.002] 16. Benham CD, Gunthorpe MJ, Davis JB. TRPV channels as temperature sensors. Cell Calcium. 2003; 33(5): 479-87. [ DOI:10.1016/S0143-4160(03)00063-0] 17. Carballo-Villalobos A, González-Trujano M, Alvarado-Vázquez N, López-Muñoz F. Pro-inflammatory cytokines involvement in the hesperidin antihyperalgesic effects at peripheral and central levels in a neuropathic pain model. Inflammopharmacology. 2017; 25(2): 265-9. [ DOI:10.1007/s10787-017-0326-3] 18. Loscalzo LM, Yow TT, Wasowski C, Chebib M, Marder M. Hesperidin induces antinociceptive effect in mice and its aglicone, hesperetin, binds to μ-opioid receptor and inhibits GIRK1/2 currents. Pharmacology Biochemistry and Behavior. 2011; 99(3): 333-41. [ DOI:10.1016/j.pbb.2011.05.018] 19. Vabeiryureilai M, Lalrinzuali K, Jagetia G. Determination of anti-inflammatory and analgesic activities of a citrus bioflavanoid, hesperidin in mice. Immunochem Immunopathol: Open Access. 2015; 1(107): 2. [ DOI:10.4172/2469-9756.1000107] 20. Ventura-Martinez R, Mares-Sánchez JJ, Avilés-Herrera J, Ángeles-López GE, Déciga-Campos M, González-Trujano ME, et al. Antinociceptive synergy between metamizole and hesperidin in a model of visceral pain in mice. Arch Med Res. 2021; 52(4): 389-96. [ DOI:10.1016/j.arcmed.2020.12.011] 21. Pinho-Ribeiro FA, Hohmann MS, Borghi SM, Zarpelon AC, Guazelli CF, Manchope MF, et al. Protective effects of the flavonoid hesperidin methyl chalcone in inflammation and pain in mice: role of TRPV1, oxidative stress, cytokines and NF-κB. Chemico-biological interactions. 2015; 228: 88-99. [ DOI:10.1016/j.cbi.2015.01.011] 22. Velázquez-González C, Cariño-Cortés R, de Lucio JAG, Ortiz MI, De la O Arciniega M, Altamirano-Báez DA, et al. Antinociceptive and anti-inflammatory activities of Geranium bellum and its isolated compounds. BMC Complementary Medicine and Therapies. 2014; 14. [ DOI:10.1186/1472-6882-14-506] 23. Silva-Correa CR, Campos-Reyna JL, Villarreal-La Torre VE, Calderón-Peña AA, Blas MVG, Aspajo-Villalaz CL, et al. Potential activity of medicinal plants as pain modulators: a review. Pharmacognosy Journal. 2021; 13(1). [ DOI:10.5530/pj.2021.13.35] 24. Liu Y, Chen Z-J, Fei Y, Yu X, Chen G. Investigating the therapeutic potential of epigallocatechin gallate (EGCG) for chronic pain management: Mechanisms, applications, and future perspectives. Fitoterapia. 2025: 106646. [ DOI:10.1016/j.fitote.2025.106646] 25. Utugi S, Sashide Y, Takeda M. (-)-Epigallocatechin-3-Gallate Suppresses Hyperexcitability in Rat Primary Nociceptive Neurons Innervating Inflamed Tissues: A Comparison with Lidocaine. Metabolites. 2025; 15(7): 439. [ DOI:10.3390/metabo15070439] 26. Ismudianto A, Airlangga PS, Putri HS. Effect of Epigallocatechin Gallate (EGCG) as an Adjuvant to Paracetamol on Pain Scale and TRPV1 Expression in a Rat Model of Neuropathic Pain. Vascular and Endovascular Review. 2025; 8(14s): 328-33. 27. Xifro X, Vidal-Sancho L, Boadas-Vaello P, Turrado C, Alberch J, Puig T, et al. Novel epigallocatechin-3-gallate (EGCG) derivative as a new therapeutic strategy for reducing neuropathic pain after chronic constriction nerve injury in mice. PLoS One. 2015; 10(4): e0123122. [ DOI:10.1371/journal.pone.0123122] 28. Kurogi M, Kawai Y, Nagatomo K, Tateyama M, Kubo Y, Saitoh O. Auto-oxidation products of epigallocatechin gallate activate TRPA1 and TRPV1 in sensory neurons. Chemical senses. 2015; 40(1): 27-46. [ DOI:10.1093/chemse/bju057] 29. Takahashi S, Kurogi M, Saitoh O. The diversity in sensitivity of TRPA1 and TRPV1 of various animals to polyphenols. Biomedical Research. 2021; 42(2): 43-51. [ DOI:10.2220/biomedres.42.43] 30. Nalli M, Ortar G, Schiano Moriello A, Di Marzo V, De Petrocellis L. Effects of curcumin and curcumin analogues on TRP channels. Fitoterapia. 2017; 122: 126-31. [ DOI:10.1016/j.fitote.2017.09.007] 31. Aggarwal R. TARGETING TRPV1 SIGNALING PATHWAY THROUGH NATURAL PRODUCTS ININFLAMMATORY CANCER. Journal of Advanced Scientific Research. 2021; 12(02 Suppl 1): 66-78. 32. Naik GG, Uniyal A, Chouhan D, Tiwari V, Sahu AN. Natural products and some semi-synthetic analogues as potential TRPV1 ligands for attenuating neuropathic pain. Current Pharmaceutical Biotechnology. 2022; 23(6): 766-86. [ DOI:10.2174/1389201022666210719155931] 33. Purba AKR, Purwanto B, Zainiyah H, Gutjahr LP. Curcumin Improves the Expression of Phospholiphase C and Transient Receptor Potential Vanilloid Type 1 on Neuronal Myometrium in Dysmenorrhea Model. Sains Malaysiana. 2025; 54(2): 557-67. [ DOI:10.17576/jsm-2025-5402-20] 34. Wang X, Zhang G, Qiao Y, Feng C, Zhao X. Crocetin attenuates spared nerve injury-induced neuropathic pain in mice. Journal of pharmacological sciences. 2017; 135(4): 141-7. [ DOI:10.1016/j.jphs.2017.08.007] 35. Erfanparast A, Tamaddonfard E, Henareh-Chareh F, editors. Central H2 histaminergic and alpha-2 adrenergic receptors involvement in crocetin-induced antinociception in orofacial formalin pain in rats. Veterinary Research Forum; 2020. 36. Abdel-Salam OM, Mózsik G. Capsaicin, the vanilloid receptor TRPV1 agonist in neuroprotection: mechanisms involved and significance. Neurochemical Research. 2023; 48(11): 3296-315. [ DOI:10.1007/s11064-023-03983-z] 37. Szallasi A. Targeting TRPV1 for cancer pain relief: can it work? Cancers. 2024; 16(3): 648. [ DOI:10.3390/cancers16030648] 38. Chung M-K, Campbell JN. Use of capsaicin to treat pain: mechanistic and therapeutic considerations. Pharmaceuticals. 2016; 9(4): 66. [ DOI:10.3390/ph9040066] 39. Heydarian S. Drug Nanocarriers as a Potential Therapeutic Strategy in Glioblastoma Multiforme. The Neuroscience Journal of Shefaye Khatam. 2023; 11(3): 110-26. [ DOI:10.61186/shefa.11.3.110] 40. Tondro G, Rajabzade G, Mohammadi A, Moradi H, Sahab Negah S. Anti-Inflammatory Effects of Nano- Curcumin on a Glioblastoma Cell Line. The Neuroscience Journal of Shefaye Khatam. 2022; 10(3): 48-56. [ DOI:10.52547/shefa.10.3.48] 41. Sadoughi D, Khayatzadeh J. Effect of Curcumin on Hippocampal Levels of Brain-Derived Neurotrophic Factor and Serum Levels of Inflammatory Cytokines in Rat Model for Alzheimer's Disease. The Neuroscience Journal of Shefaye Khatam. 2018; 6(1): 1-9. [ DOI:10.29252/shefa.6.1.1]
|